JPWO2020106708A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020106708A5 JPWO2020106708A5 JP2021517768A JP2021517768A JPWO2020106708A5 JP WO2020106708 A5 JPWO2020106708 A5 JP WO2020106708A5 JP 2021517768 A JP2021517768 A JP 2021517768A JP 2021517768 A JP2021517768 A JP 2021517768A JP WO2020106708 A5 JPWO2020106708 A5 JP WO2020106708A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- peptide
- amino acid
- residue
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 138
- 102000004196 processed proteins & peptides Human genes 0.000 claims 103
- 229920001184 polypeptide Polymers 0.000 claims 92
- 125000003275 alpha amino acid group Chemical group 0.000 claims 31
- 239000000018 receptor agonist Substances 0.000 claims 18
- 229940044601 receptor agonist Drugs 0.000 claims 18
- 230000008685 targeting Effects 0.000 claims 12
- 125000000539 amino acid group Chemical group 0.000 claims 10
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical group N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108091008875 B cell receptors Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 2
- 102000018697 Membrane Proteins Human genes 0.000 claims 2
- 108010052285 Membrane Proteins Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- -1 folic acid Chemical class 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024175673A JP2025013348A (ja) | 2018-11-20 | 2024-10-07 | 分割インターロイキン模倣体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770152P | 2018-11-20 | 2018-11-20 | |
| US62/770,152 | 2018-11-20 | ||
| PCT/US2019/062198 WO2020106708A1 (en) | 2018-11-20 | 2019-11-19 | Split interleukin mimetics and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024175673A Division JP2025013348A (ja) | 2018-11-20 | 2024-10-07 | 分割インターロイキン模倣体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022511390A JP2022511390A (ja) | 2022-01-31 |
| JP2022511390A5 JP2022511390A5 (https=) | 2022-11-24 |
| JPWO2020106708A5 true JPWO2020106708A5 (https=) | 2022-11-24 |
Family
ID=69500815
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517768A Pending JP2022511390A (ja) | 2018-11-20 | 2019-11-19 | 分割インターロイキン模倣体およびその使用 |
| JP2024175673A Pending JP2025013348A (ja) | 2018-11-20 | 2024-10-07 | 分割インターロイキン模倣体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024175673A Pending JP2025013348A (ja) | 2018-11-20 | 2024-10-07 | 分割インターロイキン模倣体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12234572B2 (https=) |
| EP (1) | EP3883956A1 (https=) |
| JP (2) | JP2022511390A (https=) |
| KR (1) | KR20210094531A (https=) |
| CN (2) | CN112912388A (https=) |
| AU (1) | AU2019384523B2 (https=) |
| BR (1) | BR112021008985A2 (https=) |
| CA (1) | CA3119472A1 (https=) |
| EA (1) | EA202190593A1 (https=) |
| IL (1) | IL283217A (https=) |
| MX (1) | MX2021005593A (https=) |
| SG (1) | SG11202103045SA (https=) |
| WO (1) | WO2020106708A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3810640A1 (en) * | 2018-06-25 | 2021-04-28 | University of Washington | De novo design of potent and selective interleukin mimetics |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP3883956A1 (en) | 2018-11-20 | 2021-09-29 | University of Washington | Split interleukin mimetics and their use |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| EP4288548A4 (en) * | 2021-02-05 | 2025-01-15 | Dharmacon, Inc. | FUSION PROTEINS FOR CRISPR-BASED TRANSCRIPTION REPRESSION |
| WO2023044318A2 (en) * | 2021-09-15 | 2023-03-23 | Neoleukin Therapeutics, Inc. | Interleukin-2 receptor βeta (il-2rβ) binding polypeptides |
| CN118715024A (zh) * | 2022-01-24 | 2024-09-27 | 诺夫免疫股份有限公司 | 用于细胞因子信号传导通路的选择性激活的组合物和方法 |
| IL322524A (en) | 2023-03-07 | 2025-10-01 | Chugai Pharmaceutical Co Ltd | Conditional receptor signaling via scaffolding protein |
| EP4722235A1 (en) * | 2023-05-24 | 2026-04-08 | Nantong Yichen Biopharma. Co. Ltd. | Polypeptide, and conjugate and use thereof |
| TW202519542A (zh) * | 2023-07-13 | 2025-05-16 | 美商奧特佩斯生化股份有限公司 | 經設計之細胞激素組合物及使用方法 |
| WO2025212606A1 (en) * | 2024-04-01 | 2025-10-09 | Bio-Techne Corporation | Synthetic il-2 polypeptides and conjugates, compositions, and uses thereof |
| WO2026039791A1 (en) * | 2024-08-16 | 2026-02-19 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il2 receptor agonists |
| WO2026078029A1 (en) * | 2024-10-10 | 2026-04-16 | F. Hoffmann-La Roche Ag | Splitted interleukin-2 prodrugs and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1015080A (en) | 1908-04-17 | 1912-01-16 | George I Rockwood | Apparatus for operating alarms or other devices. |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| GB0019638D0 (en) * | 2000-08-09 | 2000-09-27 | European Molecular Biology Lab Embl | Peptide mimetics |
| MXPA03011158A (es) | 2001-06-07 | 2004-02-27 | Wyeth Corp | Estructura de solucion de il - 13 y sus usos. |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| US20110020269A1 (en) | 2007-05-08 | 2011-01-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
| US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| US9428567B2 (en) | 2010-12-22 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of interleukin-2 receptor |
| US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| US9777070B2 (en) | 2014-04-30 | 2017-10-03 | Pfizer Inc | Anti-PTK7 antibody-drug conjugates |
| WO2016025385A1 (en) | 2014-08-11 | 2016-02-18 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| WO2018153865A1 (en) | 2017-02-24 | 2018-08-30 | Philogen S.P.A. | Immunoconjugates with optimized linkers and orientation |
| ES2894731T3 (es) | 2017-03-15 | 2022-02-15 | Silverback Therapeutics Inc | Compuestos de benzazepina, conjugados y usos de los mismos |
| EP3810640A1 (en) | 2018-06-25 | 2021-04-28 | University of Washington | De novo design of potent and selective interleukin mimetics |
| EP3883956A1 (en) | 2018-11-20 | 2021-09-29 | University of Washington | Split interleukin mimetics and their use |
| EP3883585A4 (en) | 2018-11-20 | 2022-12-14 | Innovative Cellular Therapeutics Holdings, Ltd. | MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF |
| JP2022553370A (ja) | 2019-10-25 | 2022-12-22 | ネオルーキン セラピューティクス，インコーポレイティド | Ｉｌ－２受容体作動薬の投与方法 |
| US20230331858A1 (en) | 2019-12-24 | 2023-10-19 | Neoleukin Therapeutics, Inc. | Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor |
| CN111040981A (zh) | 2019-12-26 | 2020-04-21 | 南昌大学 | 表达重组IL-2的重组大肠杆菌Nissle 1917及其功能验证方法 |
| EP4121449A2 (en) | 2020-03-16 | 2023-01-25 | Neoleukin Therapeutics, Inc. | Interleukin-2 receptor beta (il-2rb) binding polypeptides |
-
2019
- 2019-11-19 EP EP19848950.2A patent/EP3883956A1/en active Pending
- 2019-11-19 JP JP2021517768A patent/JP2022511390A/ja active Pending
- 2019-11-19 CN CN201980070569.6A patent/CN112912388A/zh active Pending
- 2019-11-19 AU AU2019384523A patent/AU2019384523B2/en active Active
- 2019-11-19 CN CN202510054463.4A patent/CN120040576A/zh active Pending
- 2019-11-19 MX MX2021005593A patent/MX2021005593A/es unknown
- 2019-11-19 WO PCT/US2019/062198 patent/WO2020106708A1/en not_active Ceased
- 2019-11-19 BR BR112021008985-3A patent/BR112021008985A2/pt not_active IP Right Cessation
- 2019-11-19 EA EA202190593A patent/EA202190593A1/ru unknown
- 2019-11-19 KR KR1020217014525A patent/KR20210094531A/ko not_active Ceased
- 2019-11-19 SG SG11202103045SA patent/SG11202103045SA/en unknown
- 2019-11-19 CA CA3119472A patent/CA3119472A1/en active Pending
- 2019-11-19 US US17/294,807 patent/US12234572B2/en active Active
-
2021
- 2021-05-16 IL IL283217A patent/IL283217A/en unknown
-
2024
- 2024-10-07 JP JP2024175673A patent/JP2025013348A/ja active Pending
-
2025
- 2025-01-10 US US19/016,343 patent/US20250179690A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020106708A5 (https=) | ||
| CN115057936B (zh) | 异源二聚体多特异性抗体形式 | |
| JP2017529067A5 (https=) | ||
| JP2023123649A5 (https=) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| RU2016151645A (ru) | Биспецифические гетеродимерные диантитела и их применение | |
| JPWO2019234220A5 (https=) | ||
| JP2014500868A (ja) | 癌及び慢性感染の治療のための作動薬活性を有するｉｌ−２由来のポリペプチド | |
| RU2013102953A (ru) | Полипептиды | |
| RU2007116973A (ru) | Терапевтические средства с пониженной токсичностью | |
| JP2017514515A5 (https=) | ||
| JP2022009816A5 (https=) | ||
| JPWO2021119429A5 (https=) | ||
| JP2025124718A5 (https=) | ||
| JPWO2020206330A5 (https=) | ||
| JPWO2020252421A5 (https=) | ||
| CN116075524A (zh) | 转铁蛋白受体结合蛋白 | |
| JPWO2021021606A5 (https=) | ||
| KR20240164594A (ko) | 설계된 사이토카인 조성물 및 사용 방법 | |
| Ge et al. | Chimerism of avian IgY‐scFv and truncated IgG‐Fc: A novel strategy in cross‐species antibody generation and enhancement | |
| JP2022511280A (ja) | 免疫調節特性を有するペプチド | |
| US11147854B2 (en) | Peptides having immunomodulatory properties | |
| WO2025015322A1 (en) | Designed interleukin-2 cytokine compositions and methods for use | |
| JPWO2022200525A5 (https=) | ||
| US20250382633A1 (en) | Adenoviral vectors |